GSK
3 years ago ⋅ English ⋅ 6 min read
Newsroom
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO

For media and investors onlyIssued: 9 September 2021, London UKData demonstrate potential of oncology pipeline and reinforce the importance of JEMPERLI (dostarlimab) and ZEJULA (nirapar... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK Consumer Healthcare leads oral care industry with launch of its first carbon neutral toothbrush

For media and investors onlyIssued: 6 September 2021, London UKGSK Consumer Healthcare (GSKCH), the world-leading consumer healthcare business, whose brands include Sensodyne, parodonta... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

For media and investors onlyIssued: London, UK and Seoul, Republic of Korea- Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data- Global clinical trial... Read More
GSK
3 years ago ⋅ English ⋅ 10 min read
Newsroom
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours

For media and investors onlyIssued: 17 August 2021, London UK- Second FDA approved indication for dostarlimab in 2021- GARNET study demonstrated objective response rate of 41.6% across... Read More
GSK
3 years ago ⋅ English ⋅ 6 min read
Newsroom
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

For media and investors onlyIssued: London UK and Tübingen, Germany / Boston, USA- Preclinical study provides evidence for strongly improved immune responses with second-generation... Read More
GSK
3 years ago ⋅ English ⋅ 6 min read
Newsroom
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps

For media and investors onlyIssued: 29 July 2021, London UKFirst IL-5 therapy approved as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps to targe... Read More